Study guide

9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales

New York MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the NY MPJE Exam 1.2 Study Strategy & Federal vs. New York Law Hierarchy

2 Federal Pharmacy Law: Controlled Substances

2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Registration, Forms & Security 2.3 Federal Food, Drug, and Cosmetic Act (FDCA)

3 Federal Pharmacy Law: Privacy & Supply Chain

3.1 HIPAA & Patient Privacy 3.2 OBRA '90, Medicare/Medicaid & DUR 3.3 DSCSA & Drug Supply Chain Integrity

4 Area 1a: NYSED, Board & Pharmacist Licensure

4.1 NYSED Office of the Professions, Board of Pharmacy & Education Law Article 137 4.2 Pharmacist Licensure: Education, NAPLEX/MPJE & Internship 4.3 License by Endorsement, Renewal & Continuing Education

5 Area 1b: Interns, Technicians & Discipline

5.1 Pharmacy Interns & Limited Permits 5.2 Registered Pharmacy Technicians (RPhT) & Supervision Ratios 5.3 Professional Misconduct, Discipline & Impaired Practitioner Programs

6 Area 2a: Prescribing, Controlled Substances & Collaborative Practice

6.1 Prescription Requirements & Practitioner Authority 6.2 Controlled Substance Prescribing & the NY EPCS Mandate 6.3 Refills & Authority Limitations 6.4 Collaborative Drug Therapy Management (§6801-a) & Non-Patient-Specific Orders

7 Area 2b: Counseling, Immunization & Public Health

7.1 Patient Counseling & Documentation 7.2 Pharmacist Immunization Authority 7.3 Naloxone Access & Public Health Programs 7.4 Patient Confidentiality & Pharmacy Records

8 Area 3a: Verification, Transfers & DUR/I-STOP

8.1 Legitimate Medical Purpose & Corresponding Responsibility 8.2 Prescription Transfers Between Pharmacies 8.3 Prospective DUR & the I-STOP PMP Registry 8.4 Refill Exceptions & Emergency Dispensing

9 Area 3b: Labeling, Packaging & Substitution

9.1 Labeling of Dispensed Drugs 9.2 Packaging: PPPA & Child-Resistant Containers 9.3 Generic Substitution & Interchangeable Biologics (§6816-a) 9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales

10 Area 4a: Records, Inventories & Delivery

10.1 Ordering, Acquisition & Distribution Records 10.2 Recordkeeping, Storage & Handling 10.3 Controlled Substance Inventories & BNE Registration 10.4 Delivery & Mail-Order Dispensing

11 Area 4b: Compounding, Central Fill & Facilities

11.1 Compounding: Non-Sterile, Sterile & Hazardous Drugs 11.2 Central Fill, Centralized Processing & Shared Pharmacy Services 11.3 Automated Dispensing & Telepharmacy 11.4 Pharmacy Establishment Registration, Inspections & Discipline

12 Test-Day Strategy & Final Review

12.1 When New York Law Is Stricter Than Federal Law 12.2 Test-Day Strategy & Common Traps

9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales

Key Takeaways Explain This Topic AI

New York has never enacted a state pseudoephedrine sales statute; pharmacies rely solely on the federal CMEA limits of 3.6 g/day and 9 g/30-days per purchaser.

General Business Law § 391-oo — the section number several failed meth-precursor bills would have occupied — currently governs OTC diet pills and dietary supplements, not pseudoephedrine.

General Business Law § 833 bars retail sale of dextromethorphan (DXM) products to anyone under 18 without a valid prescription, with a $250 civil penalty per violation.

Public Health Law § 3309's statewide standing order (effective August 15, 2022) lets any New York-licensed pharmacist dispense naloxone without a patient-specific prescription.

Public Health Law § 3381 (the Expanded Syringe Access Program) allows pharmacies to sell hypodermic needles and syringes without a prescription to persons 18 and older, without pharmacy registration since a 2021 amendment.

Last updated: July 2026

The Legend/OTC Baseline Behind Every BTC Rule

Every restriction in this section sits on top of the same federal foundation: the Durham-Humphrey Amendment of 1951 (FDCA § 503(b)), which split drugs into legend (prescription) products — labeled "Rx only" and unsafe for unsupervised self-use — and OTC products generally recognized as safe and effective (GRAS/GRASE) for self-selection and self-administration with adequate labeling. A behind-the-counter (BTC) product, like pseudoephedrine, is legally an OTC drug — no prescription is required — but access is restricted to the point of sale (locked case, pharmacy staff release) rather than an open shelf. Keeping this three-tier structure straight (legend vs. OTC vs. BTC) prevents a common MPJE error: treating a BTC product as though it were legend, or a legend product as though counter placement alone could make it OTC.

No New York-Specific Pseudoephedrine Statute — A Federal-Only Rule

This is one of the most commonly mis-answered MPJE topics: New York has never enacted a state statute duplicating the federal Combat Methamphetamine Epidemic Act (CMEA) . Bills to codify CMEA-style limits into New York's General Business Law were introduced repeatedly — for example, S.5036 (2011), S.627 (2015), S.1236 (2017), and A.6720 (2019) — but none were enacted. The General Business Law section number those bills would have occupied, § 391-oo , was later used for an unrelated law governing the retail sale of OTC diet pills and dietary supplements for weight loss or muscle building , not methamphetamine precursors. A pharmacist practicing in New York is bound by the federal CMEA framework alone for pseudoephedrine (PSE) and ephedrine sales:

  • Federal CMEA requirement Detail
  • Daily purchase limit 3.6 grams of PSE/ephedrine base per purchaser per day
  • 30-day purchase limit 9 grams of PSE/ephedrine base per purchaser per 30-day period
  • Point of sale Behind the counter or in a locked case — not on an open, self-select shelf
  • Photo ID Required at the point of sale

Logbook Purchaser name, address, product/quantity, date/time, and ID information recorded (electronic or paper)

Because there is no New York statute layered on top, an MPJE question describing a New York-specific PSE quantity threshold or a New York-only PSE logbook statute is testing a trap — the correct answer is that New York relies on the federal floor with no additional state law.

Dextromethorphan (DXM): A True New York-Specific Restriction

Unlike pseudoephedrine, dextromethorphan is independently restricted under New York law. General Business Law § 833 prohibits any retail establishment — not just pharmacies — from selling a product containing DXM as an active ingredient to a person under 18 without a valid prescription. Retailers must verify age unless the purchaser reasonably appears to be at least 25. Violations carry a civil penalty of $250 per violation . On the exam, remember that New York's DXM restriction is an age-based, point-of-retail-sale rule that applies broadly , not a pharmacy-only or behind-the-counter placement rule the way federal PSE restrictions are.

Naloxone: Statewide Standing Order Under PHL § 3309

New York authorizes non-patient-specific dispensing of naloxone under Public Health Law § 3309 . Since a statewide standing order took effect August 15, 2022 , any New York-licensed pharmacist (or supervised pharmacy intern) may dispense naloxone to a person requesting it, or to someone positioned to assist a person at risk of overdose, without a patient-specific prescription . § 3309 also provides that acquiring, possessing, or using an opioid antagonist under this authority does not constitute the unlawful practice of a profession. Separately, the FDA approved certain naloxone nasal spray products for fully OTC sale (no prescription or standing-order pathway needed at all) in 2023 — meaning some naloxone formulations are federally OTC while others remain accessible only through New York's non-patient-specific standing-order pathway. A pharmacist should know both routes exist and which applies to the specific product on the shelf.

Nonprescription Syringe Sales: PHL § 3381 (ESAP)

New York's Expanded Syringe Access Program (ESAP) , codified at Public Health Law § 3381 , allows pharmacies to sell hypodermic needles and syringes without a prescription to persons 18 years of age or older . Since a 2021 amendment (Chapter 433 of the Laws of 2021), pharmacies no longer need to register with the Department of Health to participate. Pharmacies selling under ESAP must keep syringes accessible only to pharmacy staff — not openly displayed for self-service — and must provide the required safety insert with each sale.

Putting the OTC/BTC Landscape Together

  • Product New York-specific rule beyond the federal baseline? Age/quantity limit
  • Pseudoephedrine/ephedrine No — federal CMEA only 3.6 g/day, 9 g/30-day (federal)
  • Dextromethorphan Yes — GBL § 833 Under 18 without a prescription
  • Naloxone Yes — PHL § 3309 standing order None — statewide non-patient-specific access
  • Syringes/needles (ESAP) Yes — PHL § 3381 18 and older only
  • Common MPJE Traps

Assuming New York has its own PSE quantity-limit or logbook statute — it does not; the federal CMEA is the sole controlling rule.

Confusing GBL § 391-oo (diet pills/dietary supplements) with a meth-precursor law — the section number was reused after the earlier precursor bills failed to pass.

Treating naloxone as requiring a patient-specific prescription in New York — the statewide standing order under PHL § 3309 removes that requirement.

Forgetting the 18-and-older threshold for nonprescription syringe sales under ESAP.